Popular on EntSun
- IRF Builders Forum Brings Global Leaders to Washington, D.C. to Advance Religious Freedom Through Cooperative Engagement - 227
- BillBoards Inc. Hits the Road with God Bless America Tour and Reality Series Now Streaming on Tubi TV - 173
- databahn Launches GenAI Sales Intelligence Platform to Revolutionize Fortune 500 and Global 2000 Account Research - 134
- Byrd Davis Alden & Henrichson Launches Independence Day Safe Ride Initiative with 500 Free Uber Credits - 126
- The ITeam Ranked on Channel Partners 2025 MSP 501—Tech Industry's Most Prestigious List of Managed Service Providers Worldwide - 119
- Revolutionary Blockchain Platform Okh Finance Announces Okh Finance(OKKH) Token Launch to Transform Global Asset Leasing Market - 119
- Agreement to Supply US-Based Defense Provider with Thin-Film Solar Tech for Orbital Application; Ascent Solar Technologies, Inc. (N A S D A Q: ASTI) - 117
- NYC Leadership Strategist Stacie Selise Launches Groundbreaking 4S Framework Series to Redefine Executive Excellence - 113
- Easton & Easton, LLP Files Suit Against The Dwelling Place Anaheim & Vineyard USA Over Abuse Allegations - 107
- The Sessions Studios Secures $300 Million Commitment to Launch World-Class Studio and 15-Film Global Slate - 106
Similar on EntSun
- Pixel Studio Productions Launches Same-Day Headshots in Houston
- Exelon Leader Tamla Olivier Named 2025 Technologist of the Year by Waves of Change STEM Conference
- Be Part of the World's Largest Art Biennale | Moons, Castles, Trees | Copenhagen Chronotopes
- SeedList Launching Institutional Crypto Crowdfunding Project to Empower Retail Investors and Disrupt the VC-Dominated Crypto Fundraising Landscape
- Rent Like A Champion Acquires CollegeWeekends
- Sumter Landing Dental Care Launches Summer Special on Full Mouth Reconstruction
- databahn Announces Subscription Access to Fortune 500 GenAI Deep Dive Sales Intelligence Reports
- AI startup Congero offers instant websites with 24/7 updates - aiming to replace web agencies
- CelluHeal™ Launches Full Line of Advanced Wound Dressings for Online Purchase in the USA, Canada, and Beyond
- Dr. Harmon Completes Prestigious Zygomatic Implant Residency in Brazil
Rhenium-SCT® (SCT= Skin Cancer Therapy) now being offered in Hanau, Germany
EntSun News/10776330
The interregional professional association for nuclear medicine in Hanau is the first treatment center in Germany offering Rhenium-SCT® for the treatment of non-melanoma skin cancer
MUNICH, Germany - May 13, 2019 - EntSun -- May 13 2019, Garching n. Munich, Germany– OncoBeta® GmbH, a commercial stage Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanocytic Skin Cancers (NMSCs), is pleased to announce that the interregional professional association for nuclear medicine in Hanau now offers the Rhenium-SCT ® (SCT= Skin Cancer Therapy) as the first treatment center in Germany.
With approximately 50.000 outpatient examinations annually, the interregional professional association for nuclear medicine Hanau is one of the biggest nuclear medicine service providers in Hesse. The offered services include a variety of different modern treatment and diagnostic methods which are state-of the art in science and technology.
"Offering NMSC skin cancer patients a highly efficient, painless, innovative therapy with excellent aesthetic results was the driving reason to establish this treatment method in our clinic," says Dr. med. Lutz-Hendrik Holle, Medical Director of Nuclear Medicine in Hanau.
"We are delighted that our innovative skin cancer therapy Rhenium-SCT® is now being offered by the Nuclear Medicine in Hanau and we are looking forward to this collaboration", states Shannon D. Brown III, CEO and Managing Director of OncoBeta® GmbH. "For us, this is an important step to offer the treatment method in addition to Italy, South Africa and Australia now also in Germany. In order to provide our treatment to as many skin cancer patients as possible, it is of course our goal to offer the availability of the therapy nationwide in Germany in the future."
More on EntSun News
The global incidence of non-melanoma skin cancers has been drastically increasing over the past decades. Depending on the source, it is estimated that there are over 5 million non-melanoma skin cancer cases reported globally each year. In Germany the number of newly diagnosed patients is about 200,000 annually and it is assumed that this number increases within the next years. To serve the increasing medical need for innovative therapies in this field and to improve the quality of patients' lives, OncoBeta® GmbH has developed its innovative Rhenium-SCT® which only require a single application, applied in one single session with excellent aesthetic outcomes.
If interested, patients and doctors can either contact the interregional professional association for nuclear medicine in Hanau directly or OncoBeta® GmbH.
Contact details:
Überörtliche Berufsausübungsgemeinschaft Nuklearmedizin
Nußallee 7 F
63450 Hanau
Phone.: +49 (0)6181/ 427 886-0
Email: heller-hautkrebs@nuk-hu.de
OncoBeta® GmbH
Phone: +49 (0)89/ 548 4224-0
Email: info@oncobeta.com
About the Rhenium-SCT® (Skin Cancer Therapy)
The Rhenium-SCT® is a non-invasive, painless therapy generally providing for unparalleled aesthetic results, even in cases otherwise considered difficult to treat. The Rhenium-SCT® utilizes the radioisotope Rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs (non-melanoma skin cancers). Due to the specially designed devices and accessories the Rhenium-SCT® compound never comes in direct contact with the patients' skin and the application is safe and simple for the applying physician. Most cases of non-melanoma skin cancers (Basal Cell Carcinomas and Squamous Cell Carcinomas) can be treated using the Rhenium-SCT® with a single application, applied in one single session. Scar-free healing of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment.
More on EntSun News
About OncoBeta® GmbH
OncoBeta® GmbH with its headquarters located at the Garching Technology and Founders Center GATE near Munich, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies utilizing epidermal radioisotope applications. Since its foundation, OncoBeta® GmbH has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting non-melanoma skin cancers. Since then, OncoBeta® has successfully perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards. OncoBeta® GmbH is European CE certified and has filed for regulatory approval in several other countries outside the European Union.
Find out more about the Rhenium-SCT® at https://www.oncobeta.com/
Follow us on social media:
LinkedIn: https://www.linkedin.com/company/oncobeta-gmbh/
Facebook: https://www.facebook.com/OncoBeta/
Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta®'s control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta®'s plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta® undertakes no
obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
END
With approximately 50.000 outpatient examinations annually, the interregional professional association for nuclear medicine Hanau is one of the biggest nuclear medicine service providers in Hesse. The offered services include a variety of different modern treatment and diagnostic methods which are state-of the art in science and technology.
"Offering NMSC skin cancer patients a highly efficient, painless, innovative therapy with excellent aesthetic results was the driving reason to establish this treatment method in our clinic," says Dr. med. Lutz-Hendrik Holle, Medical Director of Nuclear Medicine in Hanau.
"We are delighted that our innovative skin cancer therapy Rhenium-SCT® is now being offered by the Nuclear Medicine in Hanau and we are looking forward to this collaboration", states Shannon D. Brown III, CEO and Managing Director of OncoBeta® GmbH. "For us, this is an important step to offer the treatment method in addition to Italy, South Africa and Australia now also in Germany. In order to provide our treatment to as many skin cancer patients as possible, it is of course our goal to offer the availability of the therapy nationwide in Germany in the future."
More on EntSun News
- California Family Launches Billboard to Reach "Pardon Czar" Alice Marie Johnson
- Performance Slots Available: Collision Course Concert Series Heads to Atlanta, Tampa & Brooklyn
- Rent Like A Champion Acquires CollegeWeekends
- Sumter Landing Dental Care Launches Summer Special on Full Mouth Reconstruction
- Seligson Law Launches New Website to Support Cannabis Businesses in California and New York
The global incidence of non-melanoma skin cancers has been drastically increasing over the past decades. Depending on the source, it is estimated that there are over 5 million non-melanoma skin cancer cases reported globally each year. In Germany the number of newly diagnosed patients is about 200,000 annually and it is assumed that this number increases within the next years. To serve the increasing medical need for innovative therapies in this field and to improve the quality of patients' lives, OncoBeta® GmbH has developed its innovative Rhenium-SCT® which only require a single application, applied in one single session with excellent aesthetic outcomes.
If interested, patients and doctors can either contact the interregional professional association for nuclear medicine in Hanau directly or OncoBeta® GmbH.
Contact details:
Überörtliche Berufsausübungsgemeinschaft Nuklearmedizin
Nußallee 7 F
63450 Hanau
Phone.: +49 (0)6181/ 427 886-0
Email: heller-hautkrebs@nuk-hu.de
OncoBeta® GmbH
Phone: +49 (0)89/ 548 4224-0
Email: info@oncobeta.com
About the Rhenium-SCT® (Skin Cancer Therapy)
The Rhenium-SCT® is a non-invasive, painless therapy generally providing for unparalleled aesthetic results, even in cases otherwise considered difficult to treat. The Rhenium-SCT® utilizes the radioisotope Rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs (non-melanoma skin cancers). Due to the specially designed devices and accessories the Rhenium-SCT® compound never comes in direct contact with the patients' skin and the application is safe and simple for the applying physician. Most cases of non-melanoma skin cancers (Basal Cell Carcinomas and Squamous Cell Carcinomas) can be treated using the Rhenium-SCT® with a single application, applied in one single session. Scar-free healing of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment.
More on EntSun News
- databahn Announces Subscription Access to Fortune 500 GenAI Deep Dive Sales Intelligence Reports
- AI startup Congero offers instant websites with 24/7 updates - aiming to replace web agencies
- The Recording Academy Extends Invitation to The World's No.1 Superstar™—But He's Not Chasing the Award
- WonderDays Launches the UK's First AI Experience Gift Finder – Gifting Just Got So Much Easier!
- CelluHeal™ Launches Full Line of Advanced Wound Dressings for Online Purchase in the USA, Canada, and Beyond
About OncoBeta® GmbH
OncoBeta® GmbH with its headquarters located at the Garching Technology and Founders Center GATE near Munich, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies utilizing epidermal radioisotope applications. Since its foundation, OncoBeta® GmbH has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting non-melanoma skin cancers. Since then, OncoBeta® has successfully perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards. OncoBeta® GmbH is European CE certified and has filed for regulatory approval in several other countries outside the European Union.
Find out more about the Rhenium-SCT® at https://www.oncobeta.com/
Follow us on social media:
LinkedIn: https://www.linkedin.com/company/oncobeta-gmbh/
Facebook: https://www.facebook.com/OncoBeta/
Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta®'s control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta®'s plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta® undertakes no
obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
END
Source: OncoBeta GmbH
Filed Under: Technology
0 Comments
Latest on EntSun News
- Opteamix Launches StackRewrite.AI to Transform Enterprise Legacy Modernization
- Planet Maldek: Watcher Files Unseals Explosive New Theory About Mars' True Origins
- DatsJustice Ignites the Industry with New Single "Dead Or Alive" & Announces 2025 Tour Kickoff
- "The Pornified Generation": Dr. Chris Samuels Exposes the Toxic Alliance Between Bro Culture and Pornography That's Rewiring a Generation
- Meet a Scientologist Builds Aussie Dreams with Mike and Jonny Hibbard
- Overwhelmed: Rick Denzien's Stark and Stirring Climate Anthem
- The 2025 ESPY Awards After Party- Presented by Poppi & High Noon
- The Modern Insurance Store Expands Medicare Help Services for Seniors in Cincinnati
- Ironside HR Named Fastest-Growing Staffing Firm for Second Year
- Inframark Continues to Build Its Community Management Capabilities and Multi-Disciplinary Presence in Arizona
- ICAST 2025: The Crystal-Clear Revolution Begins at Booth #3233
- Brindle Pet Supplies Now Carries Badlands Ranch Dog Food in Canada
- $10 Million Allocated to Establish Crypto Treasury Focused on High Value Ethereum (ETH) & Bitcoin (BTC) as Long-Term Holdings for Cybersecurity Leader
- Sing For Your Supper: A Night of Musical Comedy and Drag for a Great Cause
- Cummings Graduate Institute for Behavioral Health Studies Celebrates New DBH Graduates
- $100 to $200 Million Equity Agreement with Top Digital Advisor Bitwise to Power Major Digital Asset Initiative for Bitcoin and Solana: OFA Group
- InSpired Brings World Premiere to the Weinberg Center This October
- New Collaboration Launches Corporate ESG Solution for Responsible Decommissioning and Transparent Reporting
- SlickCashLoan Launches Free Loan Calculator to Help You Plan Monthly Payments
- Hot New Fantasy Series Alert: The Key to Wonderland Captivates Readers with Dark Magic and Twisted Romance